Literature DB >> 14764745

Breakdown of tolerance to a self-peptide of acetylcholine receptor alpha-subunit induces experimental myasthenia gravis in rats.

Fulvio Baggi1, Andrea Annoni, Federica Ubiali, Monica Milani, Renato Longhi, Widmer Scaioli, Ferdinando Cornelio, Renato Mantegazza, Carlo Antozzi.   

Abstract

Experimental autoimmune myasthenia gravis (EAMG), a model for human myasthenia (MG), is routinely induced in susceptible rat strains by a single immunization with Torpedo acetylcholine receptor (TAChR). TAChR immunization induces anti-AChR Abs that cross-react with self AChR, activate the complement cascade, and promote degradation of the postsynaptic membrane of the neuromuscular junction. In parallel, TAChR-specific T cells are induced, and their specific immunodominant epitope has been mapped to the sequence 97-116 of the AChR alpha subunit. A proliferative T cell response against the corresponding rat sequence (R97-116) was also found in TAChR-immunized rats. To test whether the rat (self) sequence can be pathogenic, we immunized Lewis rats with R97-116 or T97-116 peptides and evaluated clinical, neurophysiological, and immunological parameters. Clinical signs of the disease were noted only in R97-116-immunized animals and were confirmed by electrophysiological signs of impaired neuromuscular transmission. All animals produced Abs against the immunizing peptide, but anti-rat AChR Abs were observed only in animals immunized with the rat peptide. These findings suggested that EAMG in rats can be induced by a single peptide of the self AChR, that this sequence is recognized by T cells and Abs, and that breakdown of tolerance to a self epitope might be an initiating event in the pathogenesis of rat EAMG and MG.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14764745     DOI: 10.4049/jimmunol.172.4.2697

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Identification of novel MicroRNA signatures linked to experimental autoimmune myasthenia gravis pathogenesis: down-regulated miR-145 promotes pathogenetic Th17 cell response.

Authors:  Jiao Wang; Shuangshuang Zheng; Ning Xin; Changxin Dou; Linlin Fu; Xiuying Zhang; Jing Chen; Yanyan Zhang; Deqin Geng; Chenghua Xiao; Guiyun Cui; Xia Shen; Yang Lu; Jinhua Wang; Ruiguo Dong; Yuehua Qiao; Yong Zhang
Journal:  J Neuroimmune Pharmacol       Date:  2013-09-17       Impact factor: 4.147

2.  Neutralization of interleukin-9 ameliorates symptoms of experimental autoimmune myasthenia gravis in rats by decreasing effector T cells and altering humoral responses.

Authors:  Xiuhua Yao; Qingfei Kong; Xiaoli Xie; Jinghua Wang; Na Li; Yumei Liu; Bo Sun; Ying Li; Guangyou Wang; Wenjin Li; Siying Qu; Haijun Zhao; Dandan Wang; Xijun Liu; Yao Zhang; Lili Mu; Hulun Li
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

3.  Transcriptional repressor Blimp1 regulates follicular regulatory T-cell homeostasis and function.

Authors:  Guang Yang; Xiaosu Yang; Junmei Zhang; Guancheng Li; Dandan Zheng; Anjiao Peng; Jue Hu; Liqun Xu; Baifeng Yang; Huan Yang; Wenbin Zhou; Erdem Tuzun; Jing Li
Journal:  Immunology       Date:  2017-10-19       Impact factor: 7.397

Review 4.  The emerging role of complement in neuromuscular disorders.

Authors:  John D Lee; Trent M Woodruff
Journal:  Semin Immunopathol       Date:  2021-10-27       Impact factor: 9.623

5.  Silencing miR-146a influences B cells and ameliorates experimental autoimmune myasthenia gravis.

Authors:  JunMei Zhang; Ge Jia; Qun Liu; Jue Hu; Mei Yan; BaiFeng Yang; Huan Yang; WenBin Zhou; Jing Li
Journal:  Immunology       Date:  2015-01       Impact factor: 7.397

6.  Clinical significance of detection of antibodies to fetal and adult acetylcholine receptors in myasthenia gravis.

Authors:  Qi-Guang Shi; Zhi-Hong Wang; Xiao-Wei Ma; Da-Qi Zhang; Chun-Sheng Yang; Fu-Dong Shi; Li Yang
Journal:  Neurosci Bull       Date:  2012-07-04       Impact factor: 5.203

7.  Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis.

Authors:  Lili Mu; Bo Sun; Qingfei Kong; Jinghua Wang; Guangyou Wang; Shujuan Zhang; Dandan Wang; Yumei Liu; Yixi Liu; Huixia An; Hulun Li
Journal:  Immunology       Date:  2009-03-23       Impact factor: 7.397

8.  Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors--Recommendations for methods and experimental designs.

Authors:  Mario Losen; Pilar Martinez-Martinez; Peter C Molenaar; Konstantinos Lazaridis; Socrates Tzartos; Talma Brenner; Rui-Sheng Duan; Jie Luo; Jon Lindstrom; Linda Kusner
Journal:  Exp Neurol       Date:  2015-03-18       Impact factor: 5.330

9.  Caspase-1 inhibitor ameliorates experimental autoimmune myasthenia gravis by innate dendric cell IL-1-IL-17 pathway.

Authors:  Cong-Cong Wang; Heng Li; Min Zhang; Xiao-Li Li; Long-Tao Yue; Peng Zhang; Yue Zhao; Shan Wang; Ruo-Nan Duan; Yan-Bin Li; Rui-Sheng Duan
Journal:  J Neuroinflammation       Date:  2015-06-14       Impact factor: 8.322

10.  Deficits in endogenous adenosine formation by ecto-5'-nucleotidase/CD73 impair neuromuscular transmission and immune competence in experimental autoimmune myasthenia gravis.

Authors:  Laura Oliveira; Alexandra Correia; Ana Cristina Costa; Sónia Guerra-Gomes; Fátima Ferreirinha; Maria Teresa Magalhães-Cardoso; Manuel Vilanova; Paulo Correia-de-Sá
Journal:  Mediators Inflamm       Date:  2015-01-27       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.